Share ownership Bolt Biotherapeutics, Inc.

BOLT

US0977022039

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 16:35:07 10/04/2026 BST			5-day change	1st Jan Change
4.690 ^USD	+3.99%		-4.87%	-14.23%

03-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-11	Bolt Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI

Share class: Bolt Biotherapeutics, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	38,273,002	36,950,219 ( 96.54 %)	0	96.54 %

Major shareholders: Bolt Biotherapeutics, Inc.

Name	Equities	%	Valuation
Sofinnova Investments, Inc. 7.175 %	137,721	7.175 %	622 499 $
Pivotal Bioventure Partners Investment Advisor LLC 4.558 %	87,486	4.558 %	395 437 $
Vivo Capital LLC 3.773 %	72,414	3.773 %	327 311 $
Renaissance Technologies LLC 2.867 %	55,025	2.867 %	248 713 $
T3 Companies LLC 1.98 %	38,000	1.98 %	171 760 $
Board of Trustees of the Leland Stanford Junior University 1.874 %	35,977	1.874 %	162 616 $
TORAY INDUSTRIES, INC. 1.869 %	35,875	1.869 %	162 155 $
PFIZER INC. 1.631 %	31,305	1.631 %	141 499 $
Nano Cap New Millennium Growth Fund LP 1.068 %	20,500	1.068 %	92 660 $
Geode Capital Management LLC 0.9796 %	18,803	0.9796 %	84 990 $
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	21.43%
Other	4.92%
Toray Industries, Inc.	1.87%
Pfizer Inc.	1.63%
Individuals	0.22%
Unknown	69.93%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	27.98%
Japan	1.87%
Individuals	0.22%

Based on 1000 largest holdings

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. It developed a lead agonist antibody that binds to Dectin-2 and activates human tumor-associated macrophages. It is developing multiple Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Employees

Sector

Biotechnology & Medical Research

More about the company